Search

for
Search:

Glossarydeuruxolitinib

medication inhibiting enzymes to treat autoimmune hair loss

Deuruxolitinib is a medication that inhibits Janus kinase (JAK) enzymes, which are involved in the inflammatory process. It is being studied for its potential to treat conditions like alopecia areata, an autoimmune disorder that causes hair loss, by reducing the immune system's attack on hair follicles.

Related Terms

Research

5 / 148 results

research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

63 citations , July 2024 in “Journal of the American Academy of Dermatology”

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata

3 citations , November 2024 in “Clinical Research”

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial

2 citations , November 2025 in “Journal of the American Academy of Dermatology”

Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.

research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients

2 citations , October 2025 in “Frontiers in Medicine”

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials

2 citations , September 2024 in “Journal of the American Academy of Dermatology”

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

View more "deuruxolitinib" in research →

Community Join

1 / 1000+ results

community Ruxolitinib - Start of a case study

in Research/Science 10 upvotes 2 years ago

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

View more "deuruxolitinib" in community →

Learn

1 / 801 results

learn Tofacitinib

a JAK inhibitor for alopecia areata and other autoimmune conditions

View more "deuruxolitinib" in learn →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →